Maravai LifeSciences Holdings Inc. [NASDAQ: MRVI] price surged by 2.43 percent to reach at $0.79. The company report on April 8, 2021 that Maravai LifeSciences Announces Pricing of an Upsized Secondary Offering of Class A Common Stock by Selling Stockholders.
Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced the pricing of an upsized public offering of 18,000,000 shares of Maravai’s Class A common stock by certain selling stockholders that was previously announced, at a public offering price of $31.25 per share. The offering was upsized by 3,000,000 shares of Maravai’s Class A common stock from what was previously announced. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 2,700,000 shares of Maravai’s Class A common stock, which was upsized from 2,250,000 shares of Maravai’s Class A common stock. The offering is expected to close on April 12, 2021, subject to customary closing conditions.
Maravai will not receive any proceeds from the sale of shares by the selling stockholders.
A sum of 6333681 shares traded at recent session while its average daily volume was at 1.33M shares. Maravai LifeSciences Holdings Inc. shares reached a high of $34.30 and dropped to a low of $32.97 until finishing in the latest session at $33.25.
The one-year MRVI stock forecast points to a potential upside of 31.84. The average equity rating for MRVI stock is currently 1.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Maravai LifeSciences Holdings Inc. [MRVI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRVI shares is $48.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRVI stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
KeyBanc Capital Markets have made an estimate for Maravai LifeSciences Holdings Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 16, 2020. The new note on the price target was released on December 15, 2020, representing the official price target for Maravai LifeSciences Holdings Inc. stock. Previously, the target price had yet another raise to $31, while Stifel analysts kept a Buy rating on MRVI stock.
The Average True Range (ATR) for Maravai LifeSciences Holdings Inc. is set at 2.27, with the Price to Sales ratio for MRVI stock in the period of the last 12 months amounting to 31.45. The Price to Book ratio for the last quarter was 15.18, with the Price to Cash per share for the same quarter was set at 0.88. Price to Free Cash Flow for MRVI in the course of the last twelve months was 59.88 with Quick ratio for the last quarter at 2.30.
MRVI Stock Performance Analysis:
Maravai LifeSciences Holdings Inc. [MRVI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.71.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRVI stock in for the last two-week period is set at 46.05, with the RSI for the last a single of trading hit 44.34, and the three-weeks RSI is set at 47.70 for Maravai LifeSciences Holdings Inc. [MRVI]. The present Moving Average for the last 50 days of trading for this stock 34.65, while it was recorded at 33.46 for the last single week of trading.
Insight into Maravai LifeSciences Holdings Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Maravai LifeSciences Holdings Inc. [MRVI] shares currently have an operating margin of +35.52 and a Gross Margin at +69.29. Maravai LifeSciences Holdings Inc.’s Net Margin is presently recorded at +27.06.
Return on Total Capital for MRVI is now 15.76, given the latest momentum, and Return on Invested Capital for the company is 12.79. Return on Equity for this stock inclined to 66.89, with Return on Assets sitting at 8.32. When it comes to the capital structure of this company, Maravai LifeSciences Holdings Inc. [MRVI] has a Total Debt to Total Equity ratio set at 667.47. Additionally, MRVI Total Debt to Total Capital is recorded at 86.97, with Total Debt to Total Assets ending up at 46.49. Long-Term Debt to Equity for the company is recorded at 660.69, with the Long-Term Debt to Total Capital now at 86.09.
Reflecting on the efficiency of the workforce at the company, Maravai LifeSciences Holdings Inc. [MRVI] managed to generate an average of $187,532 per employee. Receivables Turnover for the company is 8.11 with a Total Asset Turnover recorded at a value of 0.31.Maravai LifeSciences Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.30 and a Current Ratio set at 2.50.
MRVI Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRVI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Maravai LifeSciences Holdings Inc. go to -6.80%.
Maravai LifeSciences Holdings Inc. [MRVI] Insider Position Details
There are presently around $3,240 million, in the hands of institutional investors. The top three institutional holders of MRVI stocks are: GTCR LLC with ownership of 27,646,515, which is approximately New of the company’s market cap and around 0.20% of the total institutional ownership; D1 CAPITAL PARTNERS L.P., holding 5,930,000 shares of the stock with an approximate value of $197.17 million in MRVI stocks shares; and FMR LLC, currently with $189.74 million in MRVI stock with ownership of nearly New of the company’s market capitalization.
Positions in Maravai LifeSciences Holdings Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 115 institutional holders increased their position in Maravai LifeSciences Holdings Inc. [NASDAQ:MRVI] by around 97,444,182 shares. Additionally, 0 investors decreased positions by around 0 shares, while 0 investors held positions by with 0 shares. The mentioned changes placed institutional holdings at 97,444,182 shares, according to the latest SEC report filing. MRVI stock had 115 new institutional investments in for a total of 97,444,182 shares, while 0 institutional investors sold positions of 0 shares during the same period.